US Bancorp’s RxSight RXST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.02K Sell
490
-3
-0.6% -$25 ﹤0.01% 3710
2025
Q4
$5.14K Buy
493
+126
+34% +$1.26K ﹤0.01% 3522
2025
Q3
$3.3K Sell
367
-644
-64% -$5.65K ﹤0.01% 3654
2025
Q2
$13.1K Buy
1,011
+801
+381% +$12K ﹤0.01% 3332
2025
Q1
$5.3K Buy
210
+155
+282% +$4.61K ﹤0.01% 3636
2024
Q4
$1.89K Sell
55
-25
-31% -$1.13K ﹤0.01% 3871
2024
Q3
$3.96K Sell
80
-132
-62% -$6.76K ﹤0.01% 3644
2024
Q2
$12.8K Sell
212
-313
-60% -$17.9K ﹤0.01% 3227
2024
Q1
$27.1K Buy
525
+100
+24% +$4.91K ﹤0.01% 2970
2023
Q4
$17.1K Buy
+425
New +$12.5K ﹤0.01% 3124

Other funds holding RXST

US Bancorp's RXST Position: Q1 2026 in Review

US Bancorp reduced its RxSight (RXST) stake by 0.61% in Q1 2026, selling an estimated $25 and leaving 490 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #3710.

US Bancorp first reported a position in RXST in Q4 2023 and has held it in 10 quarters since. The position peaked at $27.1K in Q1 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • US Bancorp held 490 shares of RxSight worth $3.02K as of Q1 2026.
  • US Bancorp sold 3 RxSight shares in Q1 2026, an estimated $25.
  • RxSight made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3710 holding.
  • US Bancorp first reported a position in RxSight in Q4 2023 and has held it in 10 quarters since.
  • US Bancorp's RxSight position peaked at $27.1K in Q1 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.